Document
false0001070081 0001070081 2020-07-01 2020-07-01


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 1, 2020
PTC THERAPEUTICS, INC.
(Exact Name of Company as Specified in Charter)
Delaware
 
001-35969
 
04-3416587
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
100 Corporate Court
 
 
South Plainfield,
NJ
 
07080
(Address of Principal Executive Offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (908) 222-7000
Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
PTCT
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     o





Item 1.02. Termination of a Material Definitive Agreement
On July 1, 2020, PTC Therapeutics, Inc. (the “Company”) terminated the Credit and Security Agreement, dated May 5, 2017, as amended, by and among the Company, MidCap Financial Trust and the additional lenders thereto (the "Credit Agreement"). In connection with the termination of the Credit Agreement, the Company repaid outstanding principal and accrued interest thereunder totaling $18.4 million and paid an additional $0.6 million in termination and exit fees. All liens and security interests securing the term loan made pursuant to the Credit Agreement were released upon termination.

Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
 
Description
104
 
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL


Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
PTC Therapeutics, Inc.
 
 
 
Date: July 2, 2020
By:
/s/ Mark Boulding
 
Name:
Mark Boulding
 
Title:
Executive Vice President and Chief Legal Officer



 v3.20.2
Cover Page Document
Jul. 01, 2020
cover page [Abstract]  
Document Type 8-K
Document Period End Date Jul. 01, 2020
Entity Registrant Name PTC THERAPEUTICS, INC.
Entity Address, State or Province DE
Contained File Information, File Number 001-35969
Entity Tax Identification Number 04-3416587
Entity Address, Address Line One 100 Corporate Court
Entity Address, City or Town South Plainfield,
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07080
City Area Code (908)
Local Phone Number 222-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol PTCT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001070081
Amendment Flag false